Patents by Inventor Stale Petter Lyngstadaas
Stale Petter Lyngstadaas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230056514Abstract: The present invention relates to a new multifunctional debridement and/or antifouling composition comprising H2O2 at a final concentration of between 0.1-5% v/v, and a composite hydrogel formulation comprising pluronic acid at a concentration of 10-40% w/v, wherein the composition is in liquid form at room temperature. The composition disclosed herein is antimicrobial and/or anti-inflammatory and is particular useful in periimplantitis treatment and implant health maintenance, in periodontitis and periodontal health and in wound care and chronic ulcer care.Type: ApplicationFiled: September 7, 2022Publication date: February 23, 2023Applicant: CORTICALIS ASInventors: Ståle Petter Lyngstadaas, Håvard J. Haugen
-
Publication number: 20230020320Abstract: Aspects of the present invention relate to an improved antimicrobial and/or anti-viral composition comprising an antimicrobial and/or anti viral mixture consisting of: H2O2 at a final concentration of between 3-7% v/v, and a poloxamer at a concentration of 0.1-10% w/v. The poloxamer is in a composite hydrogel formulation. The composition disclosed herein is antimicrobial and/or anti-viral and is particularly useful for cleaning, sterilizing, disinfecting, sanitizing, decontaminating and/or debriding biological surfaces and surfaces of biomaterials, such as when provided in a hand sanitizer, mouth wash, nasal rinse and/or for wound care and/or chronic ulcer care and use for dental prophylaxis and peri-implant health maintenance.Type: ApplicationFiled: September 7, 2022Publication date: January 19, 2023Applicant: CORTICALIS ASInventors: Ståle Petter Lyngstadaas, Håvard J. Haugen
-
Publication number: 20220176020Abstract: The present invention deals with a bone implant matrix comprising a base matrix selected from the group comprising: —acellularized or acellularized non-demineralised bone matrix of any source, —matrix of natural mineral sources, —synthetic bioceramics matrix, or combinations of the above, wherein the surface of said base matrix is coated with an statistically homo-geneous composition which is a reinforcing mixture containing at least a bio-degradable polyester or co-polymer thereof, at least a gelatine or hydrolysed gelatine and at least an artificial Proline-Rich Peptide.Type: ApplicationFiled: March 17, 2020Publication date: June 9, 2022Inventors: Giuseppe Perale, Håvard Jostein Haugen, Ståle Petter Lyngstadaas, Felice Betge
-
Publication number: 20160317704Abstract: The present invention relates to a metal oxide scaffold comprising titanium oxide. The scaffolds of the invention are useful for implantation into a subject for tissue regeneration and for providing a framework for cell growth and stabilization to the regenerating tissue. The invention also relates to methods for producing such metal oxide scaffolds and their uses.Type: ApplicationFiled: January 30, 2015Publication date: November 3, 2016Inventors: Stale Petter Lyngstadaas, Havard J. Haugen, Jan Eirik Ellingsen
-
Publication number: 20150209471Abstract: The present invention relates to a metal oxide scaffold comprising titanium oxide. The scaffolds of the invention are useful for implantation into a subject for tissue regeneration and for providing a framework for cell growth and stabilization to the regenerating tissue. The invention also relates to methods for producing such metal oxide scaffolds and their uses.Type: ApplicationFiled: January 30, 2015Publication date: July 30, 2015Inventors: Stale Petter Lyngstadaas, Havard J. Haugen, Jan Eirik Ellingsen
-
Patent number: 8821568Abstract: An implant to be used as medical or dental implant, comprising a metallic or polymeric base which is covered by the vitamin D precursor cholecalciferol. The implant can be obtained by direct covering of the polymeric or metallic base with a solution comprising cholecalciferol or also covering the base with the 7-dehydrocholesterol (7-DHC), and subsequently irradiated with UV light to induce the formation of cholecalciferol. Optionally, the coating of the implant may include an antioxidant such as vitamin E. This implant enhances osseointegration in compromised patients by means of the endogenous synthesis and activity of vitamin D in hard and mineralized tissue regeneration. Furthermore, a method to obtain these implants which comprises coating the surface of the implant directly with cholecalciferol or with a specific concentration of 7-DHC and irradiated with UV light to induce the formation of cholecalciferol.Type: GrantFiled: July 26, 2012Date of Patent: September 2, 2014Assignee: Numat Biomedical S.L.Inventors: Ståle Petter Lyngstadaas, Marta Monjo, Christiane Petzold, Jan Erik Ellingsen
-
Patent number: 8367602Abstract: The present invention relates to artificial peptides optimized for the induction and/or stimulation of mineralization and/or biomineralization. The invention also relates to the use of these artificial peptides for the induction and/or stimulation of mineralization and/or biomineralization in vivo and in vitro.Type: GrantFiled: December 21, 2007Date of Patent: February 5, 2013Assignee: Corticalis ASInventors: Stale Petter Lyngstadaas, Jan Eirik Ellingsen
-
Publication number: 20130017234Abstract: An implant to be used as medical or dental implant, comprising a metallic or polymeric base which is covered by the vitamin D precursor cholecalciferol. The implant can be obtained by direct covering of the polymeric or metallic base with a solution comprising cholecalciferol or also covering the base with the 7-dehydrocholesterol (7-DHC), and subsequently irradiated with UV light to induce the formation of cholecalciferol. Optionally, the coating of the implant may include an antioxidant such as vitamin E. This implant enhances osseointegration in compromised patients by means of the endogenous synthesis and activity of vitamin D in hard and mineralized tissue regeneration. Furthermore, a method to obtain these implants which comprises coating the surface of the implant directly with cholecalciferol or with a specific concentration of 7-DHC and irradiated with UV light to induce the formation of cholecalciferol.Type: ApplicationFiled: July 26, 2012Publication date: January 17, 2013Applicant: Numat Biomedical S.L.Inventors: Ståle Petter Lyngstadaas, Marta Monjo, Christlane Petzold, Jan Erik Ellingsen
-
Publication number: 20110166670Abstract: A medical or dental implant which contains a metal material selected from the group consisting of titanium or an alloy thereof, wherein at least part of the surface of the metal material is coated with a layer of a polyunsaturated fatty acids (PUFA). In a preferred embodiment, the implant has been exposed to UV radiation for at least 30 seconds before, simultaneously with and/or after the coating with PUFA. Depending on the concentration of polyunsaturated fatty acids on the surface, at least parts of the implant exhibits improved effect on adhesion of mineralized and/or hard tissue, such as on bone remodeling and/or improved biocompatibility, or alternatively inhibits adhesion of mineralized and/or hard tissue to the implant. The metal material is preferably titanium, the polyunsaturated fatty acid is preferably EPA.Type: ApplicationFiled: May 29, 2009Publication date: July 7, 2011Inventors: Stale Petter Lyngstadaas, Marta Monjo, Christiane Petzold, Jan Erik Ellingsen
-
Patent number: 7960347Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.Type: GrantFiled: April 14, 2010Date of Patent: June 14, 2011Assignee: Institut Straumann AGInventors: Lars Hammarstrom, Stale Petter Lyngstadaas, Stina Gestrelius
-
Publication number: 20100234298Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.Type: ApplicationFiled: April 14, 2010Publication date: September 16, 2010Applicant: INSTITUT STRAUMANN AGInventors: Lars Hammarstrom, Stale Petter Lyngstadaas, Stina Gestrelius
-
Publication number: 20100172949Abstract: The present invention relates to artificial peptides optimized for the induction and/or stimulation of mineralization and/or biomineralization. The invention also relates to the use of these artificial peptides for the induction and/or stimulation of mineralization and/or biomineralization in vivo and in vitro.Type: ApplicationFiled: December 21, 2007Publication date: July 8, 2010Applicant: NUMAT ASInventors: Stale Petter Lyngstadaas, Jan Eirik Ellingsen
-
Publication number: 20100016989Abstract: The present invention relates to a metal oxide scaffold comprising titanium oxide. The scaffolds of the invention are useful for implantation into a subject for tissue regeneration and for providing a framework for cell growth and stabilization to the regenerating tissue. The invention also relates to methods for producing such metal oxide scaffolds and their uses.Type: ApplicationFiled: December 21, 2007Publication date: January 21, 2010Applicant: NUMAT ASInventors: Stale Petter Lyngstadaas, Havard Jostein Haugen, Jan Eirik Ellingsen
-
Patent number: 7304030Abstract: The present invention relates to the surprising finding that enamel matrix, enamel matrix derivatives and/or enamel matrix proteins induce dentin regeneration. The invention thus relates to the use of a preparation of an active enamel substance for the preparation of a pharmaceutical composition for the formation or regeneration of dentin following dental procedures involving exposure of vital dental pulp tissue. In another aspect, the invention relates to a method of promoting the formation or regeneration of dentin following dental procedures involving exposure of vital dental pulp tissue, the method comprising applying an effective amount of an active enamel substance on exposed vital dental pulp tissue after dental procedures.Type: GrantFiled: June 19, 2001Date of Patent: December 4, 2007Assignee: Biora ABInventors: Ståle Petter Lyngstadaas, Stina Gestrelius
-
Patent number: 7033611Abstract: The present invention relates to the use of enamel matrix, enamel matrix derivatives and/or enamel matrix proteins as therapeutic and/or cosmetic agents. These substances are used for the manufacture of a pharmaceutical and/or cosmetic composition for actively inducing, guiding and/or stimulating connective tissue growth and thus to prevent connective tissue scarring and/or contraction in a wound cavity and/or tissue defect that is characterized by a substantial loss of tissue. The invention comprises, in particular, the use of active enamel substances for guided connective soft tissue growth and resistance to contraction in deep cavity shaped wounds following loss or removal of significant volumes of tissue, such as e.g., after surgical removal of a tumor and especially in combination with radiation therapy.Type: GrantFiled: February 21, 2002Date of Patent: April 25, 2006Assignee: Biora Bioex ABInventors: Ståle Petter Lyngstadaas, Stina Gestrelius
-
Patent number: 6979670Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins are used in the preparation of a pharmaceutical composition for promoting the take of a graft, e.g. in soft tissue such as skin or mucosa or mineralized tissue such as bone.Type: GrantFiled: March 9, 2000Date of Patent: December 27, 2005Assignee: Biora BioEx ABInventors: Ståle Petter Lyngstadaas, STina Gestrelius
-
Publication number: 20040072727Abstract: The present invention relates to the use of enamel matrix, enamel matrix derivatives and/or enamel matrix proteins as therapeutic and/or cosmetic agents. Said substances are sued for the manufacture of a pharmaceutical and/or cosmetic composition for actively inducing guiding and/or stimulating connective tissue growth and thus to prevent connective tissue scaring and/or contraction in a wound cavity and/or tissue defect that is characterised by a substantial loss of tissue. Comprised in the invention is in particular the use of active enamel substances for guided connective soft tissue growth and resistance to contraction in deep cavity shaped wounds following loss or removal of significant volumes of tissue, such as e.g. after surgical removal of a tumour and especially in combination with radiation therapy.Type: ApplicationFiled: August 22, 2003Publication date: April 15, 2004Inventors: Stale Petter Lyngstadaas, Stina Gestrelius
-
Publication number: 20030096740Abstract: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.Type: ApplicationFiled: March 9, 2000Publication date: May 22, 2003Inventors: Lars Hammarstrom, Stale Petter Lyngstadaas, Stina Gestrelius